BRCA1 and triple-negative breast carcinoma: To extend our investigations into a more clinically relevant context, we tested the effect of IFNβ treatment on pancreatic adenocarcinoma cells (CAPAN-1) and triple-negative breast cancer cells (SUM149PT and MDA-MB-436) carrying BRCA1 or BRCA2 defects and we invariably obtained the same result (Fig. 2f–k).